Syneron Bio
Both parties publicly confirmed the AstraZeneca collaboration. A 2026 financing announcement states that proceeds will advance the pipeline into clinical development; specific human oral PK data were not disclosed.
ChinaFull profile →
Company database
Profiles, sources, and comparisons are open. Choose a field on the left to see its companies.
Search & refine Filters update automatically
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
32 matching companies
Oralead Pharma
The company website confirms the Macoral® / Simgut® platform and collaboration with BrightGene. The pipeline image reviewed is historical; current clinical stages require confirmation.
ChinaFull profile →
Vilya
Uses AI to design macrocycles de novo. The website lists oral / cell-permeable approaches and an α4β7 IBD program; website percentages are not converted into clinical-stage assignments.
United StatesFull profile →
Pinnacle Medicines
Uses AI, physics-based simulation, peptide chemistry, and oral formulation development for oral immunology and cardiometabolic peptides; operates in Shanghai and Pennsylvania.
China / United StatesFull profile →
Hansoh Pharma
HS-20118 / AVR-001 is an oral IL-23R cyclic peptide with disclosed Phase 1 human data. Rights outside Greater China were licensed to Avere.
ChinaFull profile →
QIC / 큐아이씨
The website explicitly identifies an ORALINK oral α4β7 cyclic peptide co-development program with D&D at lead optimization, recorded separately from radiopharmaceutical / conjugate programs.
South KoreaFull profile →
Gilead Sciences
On 2026-10-22, the company announced a proposed acquisition of PepStar's HCXT-2001 oral macrocyclic peptide program. Its Q3 announcement confirms Phase 1; closing conditions remain outstanding.
United StatesFull profile →
Pepticom
Uses AI to design oral IL-17A/F inhibitors. The company describes fully synthetic, compact cyclic peptidomimetics containing nonnatural amino acids.
Dayra Therapeutics
Collaborates with Biogen to discover and optimize oral macrocyclic peptides for immune diseases. Named targets, candidates, and human results have not been disclosed.
CanadaFull profile →
Biogen
Industry partner for Dayra's oral macrocyclic peptide collaboration, responsible for subsequent development and potential commercialization. Its role is recorded separately from Dayra's using a shared program identifier.
United StatesFull profile →
Sunshine Guojian
An investor record describes program 629 as an oral IL-23 cyclic peptide with PK suggesting once-weekly potential. Human results and the latest stage were not confirmed in this review.
ChinaFull profile →
Processa Pharmaceuticals
An October 2026 research collaboration and exclusive option agreement with Generian advances an oral macrocyclic peptide FcRn antagonist. This research-stage program is separate from Processa’s Phase 2 small-molecule BTK inhibitor VT-7208.
United StatesFull profile →
Generian Pharmaceuticals
A company emerging from the UPMC/University of Pittsburgh ecosystem, Generian entered an October 2026 research collaboration and exclusive option arrangement with Processa for an oral macrocyclic peptide FcRn antagonist.
United StatesFull profile →
Monte Rosa Therapeutics
The website reports Novartis licensing of the VAV1 molecular glue MRT-6160 and Phase 2 studies. The NEK7 molecular glue MRT-8102 completed Phase 1 GFORCE-1; MRT-2359 is in clinical combination development.
United StatesFull profile →
Cartesian Therapeutics
Develops mRNA cell therapies, with a lead program based on ex vivo mRNA CAR-T. It also collaborates with WestGene on in vivo tLNP delivery; these approaches should be evaluated separately.
United StatesFull profile →
Replicate Bioscience
A clinical-stage self-replicating RNA technology developer spanning infectious diseases, immunology, and other therapeutic areas.
United StatesFull profile →
Aanastra
Aanastra discloses PEP-CAR, an anti-CD19 in vivo CAR-T strategy combining engineered RNA and targeting peptides for cancer and autoimmune disease. The public website does not establish a registered clinical program or validated patient outcomes.
Aera Therapeutics
AERA-109 is a targeted-LNP in vivo CAR-T candidate for B-cell-mediated autoimmune diseases, supported by mouse and nonhuman-primate studies. The pipeline projects clinical entry in the second half of 2026; a projected date is not proof that dosing has begun.
United StatesFull profile →
AlphaNa Bioscience
AlphaNa identifies AFN50 as an mRNA-based in vivo CAR-T program for autoimmune disease currently evaluated in IITs. The disclosed program is classified as investigator-initiated research; unrelated RNA programs and inconsistent codes elsewhere on the website are not used to infer additional CAR-T assets.
ChinaFull profile →
Orna Therapeutics
Develops circular RNA (oRNA) and LNP delivery. Its current LinkedIn page identifies it as a wholly owned Eli Lilly subsidiary, so it should not be treated as an independent private platform company.
United StatesFull profile →
Orbital Therapeutics
An RNA and in vivo immune reprogramming platform developer; the website identifies it as a Bristol Myers Squibb company.
United StatesFull profile →
Strand Therapeutics
STX-001 is an intratumoral self-replicating mRNA treatment encoding IL-12. The company discloses a Phase 1 study and a broader programmable RNA platform.
United StatesFull profile →
Immorna
Founded in 2019, the company develops mRNA, self-replicating RNA, and delivery platforms. In 2026 it reported early JCXH-213 results in two patients with ITP; these findings should be distinguished from formal registered-trial phases and independent validation.
ChinaFull profile →
Starna Therapeutics
Starna’s pipeline includes STR-P004 and STR-P005 in vivo CAR-T programs for autoimmune disease. An ASCO abstract describes CD19 CAR mRNA in CD8-targeted LNPs and exploratory patient dosing for STR-P004. These early findings do not establish efficacy or the stage of STR-P005.
ChinaFull profile →
Coverage expands from sourced records; this database does not claim all biopharma companies.